All
With Micrometastases in Melanoma, Complete Node Removal May be Unnecessary
June 2nd 2015When melanoma metastacizes, the lymph node to which it has spread is typically removed. But what if micrometastases are found in other nearby lymph nodes? Should patients undergo a complete dissection, or removal, of all the nodes in the area?
Removing Neck Nodes Before the Spread of Oral Cancer Saves More Lives
June 2nd 2015Removing lymph nodes in the neck before they are affected by oral squamous cell cancer is a life-saving measure and should be adopted as a new standard in treating the disease, according to the results of a phase 3 study.
Time to Progression in CLL Improves 80 Percent with Imbruvica Plus Standard Drugs
June 2nd 2015Adding the targeted drug Imbruvica to a standard combination treatment reduced the risk of disease progression by 80 percent compared with the standard combination alone in patients with pretreated CLL or SLL.
Adding Ibrance to Faslodex Delays Progression of Hormone Receptor-Positive Breast Cancer
June 1st 2015By adding the targeted drug Ibrance to the hormonal drug Faslodex, women with previously treated hormone receptor (HR)-positive, HER2-negative breast cancer delayed disease progression by more than five months.
In Relapsed NHL, Time to Progression Doubles when Gazyva is Added to Rituxan
June 1st 2015Patients with relapsed indolent non-Hodgkin lymphoma who took the anti-CD20 agent Gazyva with Treanda, rather than Treanda alone, doubled their time until further disease progression during the phase 3 GADOLIN study.
Keytruda Works Well in Cancers Marked by Faulty DNA Repair Mechanism
June 1st 2015Patients with heavily pretreated colorectal cancer who harbored genetic defects in DNA mismatch repair (MMR) experienced high response rates when treated with the PD-1 inhibitor Keytruda (pembrolizumab) in a recent study.
Opdivo Sparks Greater Survival Benefit than Docetaxel in Lung Cancers
June 1st 2015The immunotherapy Opdivo (nivolumab) has been shown to convey an overall survival (OS) benefit superior to that offered by the chemotherapy docetaxel in both nonsquamous and squamous non–small cell lung cancer (NSCLC).
Keytruda Doubles Efficacy of Only Targeted Therapy for Head and Neck Cancer
May 31st 2015The immunotherapy Keytruda (pembrolizumab), in a recent study, proved twice as effective for the treatment of head and neck cancer as Erbitux (cetuximab), the only targeted therapy indicated as a therapy for the disease.
EndBrainCancer Now Initiative Works to Support, Educate and Expand Survivorship for Patients
May 28th 2015Aug. 27, 2000, started as an ordinary day for Dellann Elliott Mydland. She and her husband Chris Elliott and their two children, then 5 and 8 years old, had just finished up a weekend at their cabin and were preparing to relax by the grill at home.
Fine-Tuning the Treatment of Melanoma
May 22nd 2015Significant strides have been made in the treatment of patients with immunotherapies and targeted therapies. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge.